Submitted by baileylynn_100964 on Mon, 02/08/2021 - 21:34

Low-dose Naltrexone Changes Levels of Inflammatory Proteins in MS, Study Shows

MS News Today
20 February 2018

Review of study "Modulation of the OGF–OGFr pathway alters cytokine profiles in experimental autoimmune encephalomyelitis and multiple sclerosis", in Exp Biol Med (Maywood), January 20018,

For many years, researchers at Penn State focused on understanding the benefits of low-dose naltrexone and its relation with OGF in health and disease, including MS. Their discovery of dysregulation in OGF expression in MS patients, and animal models could lead to prognostic biomarkers for this autoimmune disorder.

Type of Video